Fulltext

Peroxisome proliferator-activated receptor β/δ: a master regulator of metabolic pathways in skeletal muscle

Lahiri, Shawon ; Wahli, Walter

In: Hormone Molecular Biology and Clinical Investigation, 2010, vol. 4, no. 2, p. 565-573

Add to personal list
    Title
    • Peroxisome proliferator-activated receptor β/δ: a master regulator of metabolic pathways in skeletal muscle
    Author
    • Lahiri, Shawon. Center for Integrative Genomics, National Research Center "Frontiers in Genetics”, University of Lausanne, Lausanne, Switzerland
    • Wahli, Walter. Center for Integrative Genomics, National Research Center "Frontiers in Genetics”, University of Lausanne, Lausanne, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Hormone Molecular Biology and Clinical Investigation, 2010, vol. 4, no. 2, p. 565-573. Walter de Gruyter
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:303246
    Summary
    Skeletal muscle is considered to be a major site of energy expenditure and thus is important in regulating events affecting metabolic disorders. Over the years, both in vitro and in vivo approaches have established the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in fatty acid metabolism and energy expenditure in skeletal muscles. Pharmacological activation of PPARβ/δ by specific ligands regulates the expression of genes involved in lipid use, triglyceride hydrolysis, fatty acid oxidation, energy expenditure, and lipid efflux in muscles, in turn resulting in decreased body fat mass and enhanced insulin sensitivity. Both the lipid-lowering and the anti-diabetic effects exerted by the induction of PPARβ/δ result in the amelioration of symptoms of metabolic disorders. This review summarizes the action of PPARβ/δ activation in energy metabolism in skeletal muscles and also highlights the unexplored pathways in which it might have potential effects in the context of muscular disorders. Numerous preclinical studies have identified PPARβ/δ as a probable potential target for therapeutic interventions. Although PPARβ/δ agonists have not yet reached the market, several are presently being investigated in clinical trials